Omada Health's GLP-1 Companion Programs Drive Long-Term Weight Loss
On January 8, 2026, Omada Health (Nasdaq: OMDA), a leading virtual-first healthcare provider, unveiled the results of a comprehensive 12-month real-world analysis related to its GLP-1 companion programs. This analysis extends prior findings and highlights the program's effectiveness in assisting employers to navigate the complex landscape of weight loss medications while delivering significant, long-lasting health benefits.
Key Findings from the 12-Month Analysis
The study indicated that participants who adhered to the GLP-1 medication regimen for the entire year experienced an average weight loss of 18.4%, surpassing the 11.9% average weight loss recorded in similar real-world studies. Importantly, those who maintained their medication regimen achieved:
- 47% greater average weight loss on semaglutide
- 37% greater weight loss on tirzepatide
Across all program participants, including those who did not persist with their medications, the averaged weight loss reached 16.3%, nearly doubling that reported in real-world evidence.
Employer Confidence and Sustained Value
According to Wei-Li Shao, President of Omada Health, “The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits. But that promise requires persistence through real-world challenges.” He emphasizes the necessity for employers to have confidence in these programs as a means to turn medication costs into an investment in employee health.
Analysis Details
The analysis involved 965 Omada members without diabetes who participated in Omada’s Enhanced GLP-1 Care Track, which offers resources for medication support and lifestyle modifications. Utilizing pharmacy claims and clinical data over a 12-month period, the study evaluated medication adherence and health outcomes.
The results revealed that 67% of Omada members maintained their GLP-1 medication for the full year, significantly higher than the 47-49% persistence rate found in other studies. Notably, individuals who discontinued their medication early achieved an average weight loss of 13.1%, compared to just 6.8% in similar real-world cases.
A Comprehensive Approach to Weight Health
Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health, asserts, “Long term weight health is about more than medication persistence—it's about helping each person navigate their unique journey.” By offering continuous support at all stages, Omada is achieving results that exceed typical clinical trials.
Omada’s Enhanced GLP-1 Care Track not only helps members develop essential lifestyle skills but also addresses side effects and promotes muscle mass preservation while navigating medication access.
Real-World Relevance
Sarah Linke, PhD, MPH, Senior Director of Clinical & Translational Research at Omada Health, explains the importance of tracking data in real-time to ensure the program's relevance and effectiveness, noting, “Our members don’t live in lab settings—they live in the real world.”
This announcement follows Omada's recent capabilities in prescribing and managing anti-obesity medications (including GLP-1s), thereby personalizing member support.
About Omada Health
Omada Health (Nasdaq: OMDA) is dedicated to transforming healthcare for those with cardiometabolic conditions such as diabetes and obesity. Their innovative model of “Compassionate Intelligence” merges human support with advanced technology to deliver tailored care.
With over a decade of experience and significant clinical backing, Omada serves more than one million members across diverse partnerships, achieving measurable health outcomes and managing healthcare costs.